This clinical trial focuses on patients with Chronic Myeloid Leukemia (CML) who have been newly diagnosed with the disease. The study evaluates a treatment using asciminib hydrochloride, a medication that works by targeting specific proteins involved in cancer cell growth. The medication is taken by mouth in the form of tablets, with a maximum daily dose of 80 mg.

The purpose of this research is to evaluate how well the combination of asciminib with other medications that target the same cancer-causing proteins works in achieving a deep reduction in cancer cells in patients who have not received previous treatment for their disease. The treatment period lasts for 21 days, and patients will be monitored to assess how their body responds to the medication.

The study involves regular medical check-ups to monitor the patient’s health status and response to treatment. Blood tests will be performed to measure the levels of cancer cells and to check how well the patient’s organs are functioning. The medication being studied is designed to specifically target the genetic change that causes this type of leukemia, known as the Philadelphia chromosome.